Methotrexate in rheumatoid arthritis

Expert Review of Clinical Immunology

Volumn 3, Issue 1, 2007, Pages 27-33

  Chan, Edwin S L ^a   Fernandez, Patricia ^a   Cronstein, Bruce N ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; AMINOTRANSFERASE; AZATHIOPRINE; CAFFEINE; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; FOLIC ACID; FOLINIC ACID; GOLD COMPLEX; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PREDNISOLONE; SALAZOSULFAPYRIDINE;

AGE DISTRIBUTION; ALPHA 1 ANTITRYPSIN DEFICIENCY; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANTIINFLAMMATORY ACTIVITY; APHTHOUS ULCER; ARTIFICIAL VENTILATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; COUGHING; CYTOPENIA; DIABETES MELLITUS; DIARRHEA; DISEASE ACTIVITY; DISEASE PREDISPOSITION; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG UPTAKE; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HEPATITIS B; HEPATITIS C; HUMAN; HYPOALBUMINEMIA; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; LIVER TOXICITY; LONG TERM CARE; LOW DRUG DOSE; LUNG BIOPSY; LUNG DISEASE; LUNG LAVAGE; LUNG TOXICITY; LYMPHOMA; MONOTHERAPY; NAUSEA; OPPORTUNISTIC INFECTION; PATHOPHYSIOLOGY; PNEUMONIA; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SEX DIFFERENCE; SIDE EFFECT; SMOKING; SOLID TUMOR; STEATOSIS; STOMATITIS; TACHYPNEA; VOMITING;

EID: 33947253255     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/1744666X.3.1.27     Document Type: Review

References (78)

1. Yazici Y, Sokka T, Kautiainen H, Swearingen C, Kulman I, Pincus T. Long term safety of methotrexate in routine clinical care, discontinuation is unusual and rarely the result of laboratory abnormalities. Ann. Rheum. Dis. 64(2), 207-211 (2005).
2. Guidelines for the management of rheumatoid arthritis, 2002 Update. Arthritis Rheum. 46(2), 328-346 (2002).
3. Cardiel MH. First Latin American position paper on the pharmacological treatment of rheumatoid arthritis. Rheumatology (Oxford) 45(Suppl 2), ii7-ii22 (2006).
4. Seeger D, Cosulich DB, Smith J, Hultquist M. Analogs of pteroylglutamic acid. III. 4-Aminoderivatives. J. Am. Chem. Soc. 71, 1753-1758 (1949).
5. Bannwarth B, Pehourcq F, Schaeverbeke T, Dehais J. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin. Pharmacokinet. 30(3), 194-210 (1996).
6. Goldman I, Lichtenstein NS, Oliverio V. Carrier mediated transport of the folic acid analogue, methotrexate, in the L1210 leukemia cell. J. Biol. Chem. 243, 5007-5017 (1968).
7. 3-pteroylglutamate5 to dihydrofolate reductase. J. Clin. Invest. 72(3), 773-778 (1983).
8. Allegra CJ, Chabner BA, Drake JC, Lutz R, Rodbard D, Jolivet J. Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J. Biol. Chem. 260(17), 9720-9726 (1985).
9. Baggott JE, Vaughn WH, Hudson BB. Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5′-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide. Biochem. J. 236, 193-200 (1986).
10. Allegra CJ, Drake JC, Jolivet J, Chabner BA. Inhibition of phosphoribosylaminoimidazolecarboxamid e transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc. Natl Acad. Sci. (USA) 82, 4881-4885 (1985).
11. Allegra CJ, Hoang K, Yeh GC, Drake JC, Baram J. Evidence for direct inhibition of de novo purine synthesis in human MCF-7 breast cells as a principal mode of metabolic inhibition by methotrexate. J. Biol. Chem. 262, 13520-13526 (1987).
12. Chan ES, Cronstein BN. Molecular action of methotrexate in inflammatory diseases. Arthritis Res. 4(4), 266-273 (2002).
13. Matherly LH, Goldman DI. Membrane transport of folates. Vitam Horm 66, 403-456 (2003).
14. Bremnes RM, Slordal L, Wist E, Aarbakke J. Dose-dependent pharmacokinetics of methotrexate and 7-hydroxymethotrexate in the rat in vivo. Cancer Res. 49(22), 6359-6364 (1989).
15. Powis G. Dose-dependent metabolism, therapeutic effect, and toxicity of anticancer drugs in man. Drug Metab. Rev. 14(6), 1145-1163 (1983).
16. Steele WH, Stuart JF, Lawrence JR et al. Enhancement of methotrexate absorption by subdivision of dose. Cancer Chemother. Pharmacol. 3(4), 235-237 (1979).
17. Kozloski GD, De Vito JM, Kisicki JC, Johnson JB. The effect of food on the absorption of methotrexate sodium tablets in healthy volunteers. Arthritis Rheum. 35(7), 761-764 (1992).
18. Dupuis LL, Koren G, Silverman ED, Laxer RM. Influence of food on the bioavailability of oral methotrexate in children. J. Rheumatol. 22(8), 1570-1573 (1995).
19. Kremer JM, Galivan J, Streckfuss A, Kamen B. Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates. Arthritis Rheum. 29(7), 832-835 (1986).
20. Dervieux T, Lein DO, Marcelletti J, Pischel K, Smith K, Walsh M, et al. HPLC determination of erythrocyte methotrexate polyglutamates after low-dose methotrexate therapy in patients with rheumatoid arthritis. Clin. Chem. 49(10), 1632-1641 (2003).
21. Dervieux T, Furst D, Lein DO et al. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum. 50(9), 2766-2774 (2004).
22. Furst DE. Practical clinical pharmacology and drug interactions of low-dose methotrexate therapy in rheumatoid arthritis. Br. J. Rheumatol. 34(Suppl. 2), 20-25 (1995).
23. Wessels JA, de Vries-Bouwstra JK, Heijmans BT et al. Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum. 54(4), 1087-1095 (2006).
24. Duffy TH, Beckman SB, Sato JK, Nagae H, Vitols KS, Huennekens FM. Polymorphism of dihydrofolate reductase from a methotrexate-resistant subline of L1210 cells. Adv. Enzyme Regul. 23, 3-12 (1985).
25. Furst DE, Koehnke R, Burmeister LF, Kohler J, Carol I. Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. J. Rheumatol. 16(3), 313-320 (1989).
26. Pavy S, Constantin A, Pham T et al. Methotrexate therapy for rheumatoid arthritis, clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine 73(4), 388-395 (2006).
27. Bressolle F, Bologna C, Kinowski JM, Sany J, Combe B. Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients. Ann. Rheum. Dis. 57(2), 110-113 (1998).
28. The effect of age and renal function on the efficacy and toxicity of methotrexate in rheumatoid arthritis. Rheumatoid Arthritis Clinical Trial Archive Group. J. Rheumatol. 22(2), 218-223 (1995).
29. Weinblatt ME, Coblyn JS, Fox DA et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N. Engl. J. Med. 312(13), 818-822 (1985).
30. Williams HJ, Willkens RF, Samuelson CO Jr et al. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum. 28(7), 721-730 (1985).
31. Weinblatt ME, Maier AL, Fraser PA, Coblyn JS. Longterm prospective study of methotrexate in rheumatoid arthritis, conclusion after 132 months of therapy. J. Rheumatol. 25(2), 238-242 (1998).
32. Kremer JM, Lee JK. The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. Arthritis Rheum. 29(7), 822-831 (1986).
33. Alarcon GS, Lopez-Mendez A, Walter J et al. Radiographic evidence of disease progression in methotrexate treated and nonmethotrexate disease modifying antirheumatic drug treated rheumatoid arthritis patients, a meta-analysis. J. Rheumatol. 19(12), 1868-1873 (1992).
34. Pincus T, Ferraccioli G, Sokka T et al. Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis, updating a 1983 review. Rheumatology (Oxford) 41(12), 1346-1356 (2002).
35. Felson DT, Anderson JJ, Boers M et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 38(6), 727-735 (1995).
36. Genovese MC, Bathon JM, Martin RW et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis, two-year radiographic and clinical outcomes. Arthritis Rheum. 46(6), 1443-1450 (2002).
37. Lipsky PE, van der Heijde DM, St Clair EW et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N. Engl. J. Med. 343(22), 1594-1602 (2000).
38. Edwards JC, Szczepanski L, Szechinski J et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350(25), 2572-2581 (2004).
39. Kremer JM, Westhovens R, Leon M et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N. Engl. J. Med. 349(20), 1907-1915 (2003).
40. Weinblatt ME, Keystone EC, Furst DE et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate, the ARMADA trial. Arthritis Rheum. 48(1), 35-45 (2003).
41. Weinblatt ME, Keystone EC, Furst DE, Kavanaugh AF, Chartash EK, Segurado OG. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis, ARMADA 4 year extended study. Ann. Rheum. Dis. 65(6), 753-759 (2006).
42. O'Dell JR, Haire CE, Erikson N et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N. Engl. J. Med. 334(20), 1287-1291 (1996).
43. Calguneri M, Pay S, Caliskaner Z, Apras S et al. Combination therapy versus monotherapy for the treatment of patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 17(6), 699-704 (1999).
44. Boers M, Verhoeven AC, Markusse HM et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350(9074), 309-318 (1997).
45. Alarcon GS, Tracy IC, Blackburn WD, Jr. Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting longterm treatment. Arthritis Rheum. 32(6), 671-676 (1989).
46. Wolfe F, Hawley DJ, Cathey MA. Termination of slow acting antirheumatic therapy in rheumatoid arthritis, a 14-year prospective evaluation of 1017 consecutive starts. J. Rheumatol. 17(8), 994-1002 (1990).
47. Alarcon GS, Tracy IC, Strand GM, Singh K, Macaluso M. Survival and drug discontinuation analyses in a large cohort of methotrexate treated rheumatoid arthritis patients. Ann. Rheum. Dis. 54(9), 708-712 (1995).
48. Papadopoulos NG, Alamanos Y, Papadopoulos IA, Tsifetaki N, Voulgari PV, Drosos AA. Disease modifying antirheumatic drugs in early rheumatoid arthritis, a longterm observational study. J. Rheumatol. 29(2), 261-266 (2002).
49. Schnabel A, Herlyn K, Burchardi C, Reinhold-Keller E, Gross WL. Long-term tolerability of methotrexate at doses exceeding 15 mg per week in rheumatoid arthritis. Rheumatol. Int. 15(5), 195-200 (1996).
50. Dahl MG, Gregory MM, Scheuer PJ. Methotrexate hepatotoxicity in psoriasis - comparison of different dose regimens. Br. Med. J. 1(801), 654-656 (1972).
51. Walker AM, Funch D, Dreyer NA et al. Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. Arthritis Rheum. 36(3), 329-335 (1993).
52. Roenigk HH, Jr., Maibach HI, Weinstein GP. Methotrexate therapy for psoriasis. Guideline revisions. Arch. Dermatol. 108(1), 35 (1973).
53. Richard S, Guerret S, Gerard F, Tebib JG, Vignon E. Hepatic fibrosis in rheumatoid arthritis patients treated with methotrexate, application of a new semi-quantitative scoring system. Rheumatology (Oxford) 39(1), 50-54 (2000).
54. Kremer JM, Furst DE, Weinblatt ME, Blotner SD. Significant changes in serum AST across hepatic histological biopsy grades, prospective analysis of 3 cohorts receiving methotrexate therapy for rheumatoid arthritis. J. Rheumatol. 23(3), 4561-4594(1996).
55. Kremer JM, Alarcon GS, Lightfoot RW, Jr et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum. 37(3), 316-328 (1994).
56. Yazici Y, Erkan D, Paget SA. Monitoring methotrexate hepatic toxicity in rheumatoid arthritis, is it time to update the guidelines? J. Rheumatol. 29(8), 1586-1589 (2002).
57. Chan ES, Montesinos MC, Fernandez P et al. Adenosine A(2A) receptors play a role in the pathogenesis of hepatic cirrhosis. Br. J. Pharmacol. 148(8), 1144-1155 (2006).
58. Chan ES, Fernandez P, Merchant AA et al. Adenosine A2A receptors in diffuse dermal fibrosis, pathogenic role in human dermal fibroblasts and in a murine model of scleroderma. Arthritis Rheum. 54(8), 2632-2642 (2006).
59. Klatsky AL, Morton C, Udaltsova N, Friedman GD. Coffee, cirrhosis, and transaminase enzymes. Arch. Intern. Med. 166(11), 1190-1195 (2006).
60. Nesher G, Mates M, Zevin S. Effect of caffeine consumption on efficacy of methotrexate in rheumatoid arthritis. Arthritis Rheum. 48(2), 571-572 (2003).
61. Benito-Garcia E, Heller JE, Chibnik LB et al. Dietary caffeine intake does not affect methotrexate efficacy in patients with rheumatoid arthritis. J. Rheumatol. 33(7), 1275-1281 (2006).
62. Kremer JM, Alarcon GS, Weinblatt ME et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis, a multicenter study with literature review. Arthritis Rheum. 40(10), 1829-1837 (1997).
63. van der Veen MJ, Dekker JJ, Dinant HJ, van Soesbergen RM, Bijisma JW. Fatal pulmonary fibrosis complicating low dose methotrexate therapy for rheumatoid arthritis. J. Rheumatol. 22(9), 1766-1768 (1995).
64. Searles G, McKendry RJ. Methotrexate pneumonitis in rheumatoid arthritis, potential risk factors. Four case reports and a review of the literature. J. Rheumatol. 14(6), 1164-1171 (1987).
65. Alarcon GS, Kremer JM, Macaluso M et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group. Ann. Intern. Med. 127(5), 356-364 (1997).
66. Cook NJ, Carroll GJ. Successful reintroduction of methotrexate after pneumonitis in two patients with rheumatoid arthritis. Ann. Rheum. Dis. 51(2), 272-274 (1992).
67. Morgan SL, Oster RA, Lee JY, Alarcon GS, Baggott JE. The effect of folic acid and folinic acid supplements on purine metabolism in methotrexate-treated rheumatoid arthritis. Arthritis Rheum. 50(10), 3104-3111 (2004).
68. Morgan SL, Baggott JE, Vaughn WH et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. Ann. Intern. Med. 121(11), 833-841 (1994).
69. Ortiz Z, Shea B, Suarez Almazor M, Moher D, Wells G, Tugwell P. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst. Rev. 2, CD000951 (2000).
70. Joyce DA, Will RK, Hoffman DM, Laing B, Blackbourn SJ. Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folinic acid. Ann. Rheum. Dis. 50(12), 913-914 (1991).
71. Whittle SL, Hughes RA. Folate supplementation and methotrexate treatment in rheumatoid arthritis, a review. Rheumatology (Oxford) 43(3), 267-271 (2004).
72. Khanna D, Park GS, Paulus HE et al. Reduction of the efficacy of methotrexate by the use of folic acid, post hoc analysis from two randomized controlled studies. Arthritis Rheum. 52(10), 3030-3038 (2005).
73. Moder KG, Tefferi A, Cohen MD, Menke DM, Luthra HS. Hematologic malignancies and the use of methotrexate in rheumatoid arthritis, a retrospective study. Am. J. Med. 99(3), 276-281 (1995).
74. Bologna C, Picot MC, Jorgensen C, Viu P, Verdier R, Sany J. Study of eight cases of cancer in 426 rheumatoid arthritis patients treated with methotrexate. Ann. Rheum. Dis. 56(2), 97-102 (1997).
75. Georgescu L, Quinn GC, Schwartzman S, Paget SA. Lymphoma in patients with rheumatoid arthritis, association with the disease state or methotrexate treatment. Semin. Arthritis Rheum. 26(6), 794-804 (1997).
76. Bachman TR, Sawitzke AD, Perkins SL, Ward JH, Cannon GW. Methotrexate-associated lymphoma in patients with rheumatoid arthritis, report of two cases. Arthritis Rheum. 39(2), 325-329 (1996).
77. Salloum E, Cooper DL, Howe G et al. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J. Clin. Oncol. 14(6), 1943-1949 (1996).
78. Kamel OW, van de Rijn M, Weiss LM et al. Brief report, reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N. Engl. J. Med. 328(18), 1317-1321 (1993).